Levosimendan as a therapeutic strategy to prevent neuroinflammation after aneurysmal subarachnoid he...
Levosimendan as a therapeutic strategy to prevent neuroinflammation after aneurysmal subarachnoid hemorrhage?
About this item
Full title
Author / Creator
Publisher
BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundPoor patient outcomes after aneurysmal subarachnoid hemorrhage (SAH) occur due to a multifactorial process, mainly involving cerebral inflammation (CI), delayed cerebral vasospasm (DCVS), and delayed cerebral ischemia, followed by neurodegeneration. CI is mainly triggered by enhanced synthesis of serotonin (5-HT), prostaglandin F2alpha (P...
Alternative Titles
Full title
Levosimendan as a therapeutic strategy to prevent neuroinflammation after aneurysmal subarachnoid hemorrhage?
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8938656
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8938656
Other Identifiers
ISSN
1759-8478
E-ISSN
1759-8486
DOI
10.1136/neurintsurg-2021-017504
